Key Market Indicators
Austrian Antidepressant Medicine Sales are projected to plummet to approximately $42 million by 2028, a significant drop from the $69 million recorded in 2023. This decline represents an annual compound growth rate (CAGR) decrease of 8%. Since 2015, the Austrian market for antidepressants has been on a downward trajectory, with an average decrease of 5.5% year on year. In the rankings for 2023, Austria held the 9th position. The Czech Republic surpassed Austria, matching its $69 million sales figure. Meanwhile, Spain, Italy, and Australia claimed the 2nd, 3rd, and 4th spots in the global ranking for antidepressant sales, respectively.
